Endo, a wholly-owned subsidiary of Mallinckrodt plc, announced today the launch of a generic version of Amgen’s RAVICTI^® (glycerol phenylbutyrate), 1.1 gm/mL oral liquid, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Endo’s glycerol phenylbutyrate is the first and currently the only FDA-approved generic version of RAVICTI^® available in the U.S.

“This first-to-market launch of generic RAVICTI^® oral liquid is a meaningful milestone for Endo and important for our Generics business as we near the planned spin-off of Par Health,” said Scott Sims, Senior Vice President and General Manager, Endo Injectable Solutions and Generics. “It expands access for patients and providers, and reinforces our commitment to quality, reliability, and leadership in complex generics.” Read More >